Email ID
Password
Scrip   
Acute heart failure data for Corthera's relaxin data "probably too good to be true"
30 March 2009
Alex Shimmings

The US biopharmaceutical company Corthera (formerly BAS Medical) is set to take its lead product, a recombinant version of the human hormone relaxin, into Phase III by the end of this year on the back of highly promising Phase IIb data in acute heart failure (AHF).
The study, Pre-RELAX-AHF, found...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36